A detailed history of Sg Americas Securities, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 15,057 shares of CGEM stock, worth $164,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,057
Previous 85,172 82.32%
Holding current value
$164,874
Previous $1.49 Million 83.03%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$16.03 - $20.86 $1.12 Million - $1.46 Million
-70,115 Reduced 82.32%
15,057 $252,000
Q2 2024

Jul 12, 2024

BUY
$15.63 - $29.35 $1.18 Million - $2.21 Million
75,236 Added 757.21%
85,172 $1.49 Million
Q1 2024

May 06, 2024

SELL
$10.17 - $19.02 $45,897 - $85,837
-4,513 Reduced 31.23%
9,936 $169,000
Q4 2023

Jan 12, 2024

BUY
$7.89 - $10.23 $12,521 - $16,235
1,587 Added 12.34%
14,449 $147,000
Q3 2023

Oct 13, 2023

BUY
$9.05 - $11.72 $116,401 - $150,742
12,862 New
12,862 $116,000
Q1 2023

Apr 28, 2023

SELL
$10.2 - $11.91 $10,924 - $12,755
-1,071 Reduced 8.82%
11,066 $113,000
Q4 2022

Feb 02, 2023

BUY
$9.72 - $13.62 $9,224 - $12,925
949 Added 8.48%
12,137 $128,000
Q3 2022

Oct 31, 2022

SELL
$11.82 - $15.42 $16,784 - $21,896
-1,420 Reduced 11.26%
11,188 $143,000
Q2 2022

Jul 29, 2022

BUY
$7.31 - $13.55 $92,164 - $170,838
12,608 New
12,608 $162,000
Q1 2022

Apr 29, 2022

SELL
$10.47 - $16.75 $114,290 - $182,843
-10,916 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$15.36 - $25.0 $75,985 - $123,675
-4,947 Reduced 31.19%
10,916 $168,000
Q3 2021

Nov 01, 2021

BUY
$22.56 - $29.68 $357,869 - $470,813
15,863 New
15,863 $358,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $499M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.